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CD5 acts as a coreceptor on T lymphocytes and plays an important role in T-cell signaling and T-cell–B-cell
interactions. Costimulation of T lymphocytes with anti-CD5 antibodies results in an increase of the intracel-
lular Ca21 levels, and subsequently in the activation of Ca21/calmodulin-dependent (CaM) kinase type IV. In
the present study, we have characterized the initial signaling pathway induced by anti-CD5 costimulation. The
activation of phosphatidylinositol (PI) 3-kinase through tyrosine phosphorylation of its p85 subunit is a
proximal event in the CD5-signaling pathway and leads to the activation of the lipid kinase activity of the p110
subunit. The PI 3-kinase inhibitors wortmannin and LY294002 inhibit the CD5-induced response as assessed
in interleukin-2 (IL-2) secretion experiments. The expression of an inactivated Rac1 mutant (Rac1 z N17) in
T lymphocytes transfected with an IL-2 promoter-driven reporter construct also abrogates the response to CD5
costimulation, while the expression of a constitutively active Rac1 mutant (Rac1-V12) completely replaces the
CD5 costimulatory signal. The Rac1-specific guanine nucleotide exchange factor Vav is heavily phosphorylated
on tyrosine residues upon CD5 costimulation, which is a prerequisite for its activation. A role for Vav in the
CD5-induced signaling pathway is further supported by the findings that the expression of a dominant negative
Vav mutant (Vav-C) completely abolishes the response to CD5 costimulation while the expression of a
constitutively active Vav mutant [Vav(D1–65)] makes the CD5 costimulation signal superfluous. Wortmannin
is unable to block the Vav(D1–65)- or Rac1 z V12-induced signals, indicating that both Vav and Rac1 function
downstream from PI 3-kinase. Vav and Rac1 both act upstream from the CD5-induced activation of CaM
kinase IV, since KN-62, an inhibitor of CaM kinases, and a dominant negative CaM kinase IV mutant block
the Vav(D1–65)-and Rac1 z V12-mediated signals. We propose a model for the CD5-induced signaling pathway
in which the PI 3-kinase lipid products, together with tyrosine phosphorylation, activate Vav, resulting in the
activation of Rac1 by the Vav-mediated exchange of GDP for GTP.
The CD5 receptor, which is expressed on the surface of all T
lymphocytes as well as on a subset of B lymphocytes, is a
67-kDa monomeric transmembrane glycoprotein that belongs
to the scavenger receptor cysteine-rich family of extracellular
domain-like structures (1, 11, 28). The counterreceptor of CD5
has been identified as CD72, a dimeric receptor which is com-
monly expressed on B lymphocytes (63). A second ligand of
CD5, termed CD5L, is present on activated splenic B lympho-
cytes (4). In view of its involvement in the interactions between
T and B lymphocytes and also between different subsets of B
lymphocytes, it has been proposed that CD5 plays an impor-
tant role in the regulation of the immune response (4, 11, 13,
44, 57).
The CD5 receptor on T lymphocytes is associated with the
T-cell receptor (TCR)-CD3-CD4 (or CD8) complex, which
also comprises the protein tyrosine kinases p56lck and p59fyn,
and it depends on this physical association for its functional
activity (3, 8, 30, 40, 54). Once the TCR-CD3 complex is
engaged by ligand, the cytoplasmic domain of CD5 becomes
rapidly phosphorylated on tyrosine residues, as are the TCR z
chains (8, 17, 44). These tyrosines are present in a potential
tyrosine kinase phosphorylation motif (Y-X11-Y-XX), which is
similar to the immunoreceptor tyrosine activation motifs as
found in the TCR z and CD3 chains (3, 44). Once the tyrosine
residues in this motif became phosphorylated, they can serve as
docking sites for SH2 (Src homology 2) domain-containing
proteins (44, 53). The protein tyrosine kinase p56lck, which is
associated with CD4 or CD8 (50), seems to be responsible for
the phosphorylation of the tyrosine residues in the cytoplasmic
domain of the CD5 receptor upon TCR engagement. It has
also been demonstrated that p56lck binds to the cytoplasmic
domain of CD5 through its SH2 domain and becomes fully
activated once bound, probably through autophosphorylation
(44).
The costimulation of T lymphocytes via the CD5 receptor
augments the intracellular calcium and cyclic GMP levels (30,
35). Subsequently, both interleukin-2 (IL-2) secretion and IL-2
receptor expression are enhanced (1, 12, 23, 30). Recently, we
reported that costimulation of T lymphocytes with anti-CD5
antibodies results in the activation of the Ca21/calmodulin-
dependent kinase type IV (CaM kinase IV) (23). The lym-
phoid cell- and brain-specific CaM kinase IV is activated
through phosphorylation on threonine-196 by CaM kinase ki-
nase, which in turn is activated by an increase of the intracel-
lular Ca21 levels (41, 51, 59, 60). The enhanced activation of
CaM kinase IV through CD5 costimulation is associated with
an increase of the AP-1 activity at the IL-2 promoter, resulting
in an enhanced transcription and expression of the IL-2 gene
(23). The mitogen-activated protein kinases, ERK (extracellu-
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lar signal-regulated kinase), JNK (c-Jun N-terminal kinase),
and p38/Mpk2, which play an important role in the activation
of AP-1 through a multitude of extracellular stimuli (10, 61),
are not activated by the CD5-induced signaling pathway (23).
In the present study, we set out to elucidate the signaling
pathways induced by CD5 costimulation and to identify the
potential SH2 domain-containing proteins which initiate the
CD5 signal transduction route. We present evidence that phos-
phatidylinositol 3-kinase (PI 3-kinase) is activated by ligation
of the CD5 receptor and that PI 3-kinase activates Rac1
through a mechanism involving the guanine exchange factor
Vav. Most significantly, we found that the activation of both
Vav and Rac1 is indispensable for the CD5-induced signaling
pathway.
MATERIALS AND METHODS
T-lymphocyte isolation. Human peripheral blood cells were obtained from
healthy volunteer platelet donors, and mononuclear cell suspensions were pre-
pared by Ficoll-Hypaque (Lymphoprep; Nycomed, Oslo, Norway) density gra-
dient centrifugation. T lymphocytes were isolated by 2-aminoethylisothiouro-
nium bromide-treated sheep erythrocyte rosetting. The sheep erythrocytes were
lysed with 155 mM NH4Cl–10 mM KHCO3–0.1 mM EDTA by standard proce-
dures. The remaining cell preparations contained more than 98% T lymphocytes
as assessed by flow cytometric analysis after being stained with an anti-CD2
monoclonal antibody (MAb) (Becton Dickinson, Mountain View, Calif.) and less
than 1% CD14-positive cells (Becton Dickinson). After isolation, T lymphocytes
were kept overnight at 37°C in RPMI 1640 medium (BioWhittaker, Verviers,
Belgium) containing 2% fetal calf serum (FCS; HyClone, Logan, Utah) supple-
mented with 2 mM L-glutamine, 100 U of penicillin per ml, 100 mg of strepto-
mycin per ml, and 6 ng of colistin per ml.
Stimulation. Human T lymphocytes (5 3 106/ml) were incubated for various
periods with 2 mg of phytohemagglutinin (PHA; Sigma, St. Louis, Mo.) per ml in
combination with a MAb against CD28 (a gift from R. van Lier, Central Labo-
ratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam,
The Netherlands), used at a final concentration of 5% hybridoma culture super-
natant, and/or a MAb against CD5 (83-P2E6; MCA Development, Groningen,
The Netherlands), also used at 5% hybridoma culture supernatant. Various
inhibitors were added 30 to 60 min before stimulation: wortmannin (Sigma), an
inhibitor of PI 3-kinase, was used at a final concentration of 100 nM; LY294002
[2-(4-morpholinyl)-8-phenyl-4H-1-benxopyran-4-one; AleXis Corp., La¨ufelfin-
gen, Switzerland], also an inhibitor of PI 3-kinase, was used at a final concen-
tration of 1 mM; rapamycin (AleXis), which inhibits the activation of p70 S6
kinase, was used at a final concentration of 20 ng/ml; and KN-62 [1-(N,O-bis-
(5-isoquinoline-sulfonyl)-N-methyl-L-tyrosyl)-4-phenyl-piperazine; AleXis], an
inhibitor of CaM kinases, was used at a final concentration of 10 mM.
Measurement of secreted IL-2 protein. Human T lymphocytes (3 3 106/ml)
were stimulated for 24 h with PHA plus anti-CD28 in the presence or absence of
anti-CD5. Inhibitors were added 30 min before stimulation. Secreted IL-2 pro-
tein was quantified in cell-free supernatants with a human IL-2 enzyme-linked
immunosorbent assay (ELISA) kit (R&D Systems, Minneapolis, Minn.) as rec-
ommended by the manufacturer.
PKB and p70 S6K kinase activity assay. Total-cell lysates were prepared from
stimulated human T lymphocytes after 10 min of stimulation for measurement of
kinase activity. The T lymphocytes used for protein kinase B (PKB) assays were
cultured in RPMI 1640 medium supplemented with 2 mM L-glutamine and
antibiotics, containing only 0.2% FCS. T lymphocytes (5 3 107) were left un-
stimulated or stimulated with PHA and anti-CD28 in the presence or absence of
anti-CD5. The cells were harvested, washed once with phosphate-buffered saline
(PBS), resuspended in 400 ml of lysis buffer (20 mM HEPES [pH 7.4], 2 mM
EGTA, 1 mM dithiothreitol [DTT], 1% Triton X-100, 10% glycerol) supple-
mented with protease inhibitors (10 mg of leupeptin [Sigma] per ml, 10 mg of
aprotinin [Sigma] per ml, 0.4 mM phenylmethylsulfonyl fluoride [Sigma]) and
phosphatase inhibitors (50 mM b-glycerophosphate, 1 mM Na3VO4), and incu-
bated on ice for 20 min. Insoluble debris was collected by centrifugation at
1,000 3 g for 10 min by 4°C. The protein concentration of the cell lysates was
determined by the Bradford assay (5).
PKB and p70 S6K were immunoprecipitated from 800 mg of cell lysate by
incubating it with an anti-PKB polyclonal antibody (PAb) (7) or an anti-p70 S6K
PAb (sc-230; Santa Cruz Biotechnology, Santa Cruz, Calif.), respectively, for 1 h
at 4°C with rotation and an additional 18 h after the addition of 20 ml of protein
G plus agarose beads (50% slurry; Santa Cruz Biotechnology). The immunopre-
cipitates were divided in half: one part was used to confirm the equal precipita-
tion of proteins, and the other part was used for the kinase assay as described
below. For the detection of PKB and p70 S6K, the immunoprecipitates were
centrifuged in a microcentrifuge for 30 s at 4°C, washed twice times with PBS,
and then boiled in 13 sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) sample buffer. The proteins were separated by SDS-PAGE on a
12.5% gel, with Rainbow colored protein molecular weight markers (Amersham,
Little Chalfont, United Kingdom) as a reference, and transferred onto a poly-
vinylidene difluoride (PVDF; Millipore, Bedford, Mass.) membrane. The mem-
brane was blocked for 1 h in PBS containing 5% skin milk and 0.01% Tween 20.
PKB and p70 S6K were detected by incubating the membranes with anti-PKB
PAb (1:1,000 dilution) or anti-p70 S6K PAb (1:1,000) for 1 h and then with a
secondary antibody, swine anti-rabbit immunoglobulin-horseradish peroxidase
(Ig-HRP) (1:5,000; Dako, Glostrup, Denmark), for 1 h. The membranes were
then assayed with the enhanced chemiluminescence (ECL) detection system
(Amersham).
For the kinase assays, the immunoprecipitates were centrifuged in a micro-
centrifuge for 20 s at 4°C, washed three times with lysis buffer, three times with
LiCl buffer (500 mM LiCl, 100 mM Tris-HCl [pH 7.6], 1 mM DTT, 0.1% Triton
X-100), and finally three times with assay buffer (50 mM Tris-HCl [pH 7.6], 10
mM MgCl2, 1 mM DTT, 0.1% Triton X-100 [for PKB]; 50 mM morpholinepro-
panesulfonic acid [MOPS; [pH 7.2], 5 mM MgCl2, 1 mM DTT, 0.1% Triton
X-100 [for p70 S6K]). The PKB immunoprecipitates were assayed for kinase
activity in 30 ml of assay mix containing 50 mM Tris-HCl (pH 7.6), 10 mM MgCl2,
1 mM DTT, 0.1% Triton X-100, 2 mM PKI (Santa Cruz Biotechnology), 30 mM
ATP, and 5 mCi of [g-32P]ATP (3,000 Ci/mmol; Amersham) in a 20-min assay at
30°C, with 10 mg of histone 2B (Boehringer, Mannheim, Germany) as the
substrate. The p70 S6K immunoprecipitates were assayed for kinase activity in 30
ml of assay mix containing 50 mM MOPS (pH 7.2), 5 mM MgCl2, 1 mM DTT,
0.1% Triton X-100, 2 mM PKI, 30 mM ATP, and 10 mCi of [g-32P]ATP (3,000
Ci/mmol; Amersham) in a 20-min assay at 30°C, with 15 mg of S6 peptide
(sc-3009; Santa Cruz Biotechnology) as the substrate. The reactions were termi-
nated by the addition of 53 SDS-PAGE sample buffer and boiling. The proteins
were separated by SDS-PAGE on a 15% gel, with Rainbow colored protein
molecular weight markers as a reference. Phosphorylated substrates were quan-
titated with a PhosphorImaging system and the ImageQuant software (Molecular
Dynamics, Sunnyvale, Calif.)
Plasmids. The ClaI-HindIII fragment of pIL2CAT (a gift from C. L. Verweij,
Department of Rheumatology, Academic Hospital Leiden, Leiden, The Neth-
erlands) containing the IL-2 promoter from positions 2319 to 147 (64) was
subcloned in the SmaI site of the pCAT3-enhancer reporter plasmid (Promega
Corp., Madison, Wis.) to construct the reporter plasmid pCAT3e-IL2(2319/
147). The empty pCAT3-enhancer plasmid and the pCAT3-control reporter
plasmid (Promega) served as negative and positive controls, respectively, in the
transfection assays.
The expression plasmids used have been described previously. pSRa-Dp85
encodes a deletion mutant of the p85 subunit of PI 3-kinase (26). pEXV-myc-
Rac1N17, encoding a myc-tagged dominant negative mutant of Rac1, pEXV-
myc-Rac1V12, encoding a myc-tagged constitutively active mutant of Rac1, and
pEXV-myc-Cdc42 z N17, encoding a myc-tagged dominant negative mutant of
Cdc42, were provided by A. Hall, CRC Oncogene and Signal Transduction
Group, Department of Biochemistry, University College London, London,
United Kingdom (14, 49). pGBT-RhoN19, encoding a dominant inhibitory mu-
tant of Rho, was provided by M. Symons, ONYX Pharmaceuticals, Richmond,
Calif., and was subcloned in the pCS21 expression vector by R. van Weeghel,
Department of Genetics, University of Groningen, Haren, The Netherlands (14).
pME18S-dn CaMKIV, encoding a dominant negative mutant of CaM kinase IV,
was kindly provided by T. R. Soderling, Vollum Institute, Oregon Health Sci-
ences University, Portland, Oreg. (23). pEF-myc-Vav-C, encoding a myc-tagged
dominant negative form of Vav, was provided by A. Weiss, Howard Hughes
Medical Institute, Department of Medicine, University of California, San Fran-
cisco, Calif. (71). pMEX-Vav(D1–65), encoding the constitutively active onco-
protein Vav, was provided by X. R. Bustelo, Department of Pathology, Univer-
sity Hospital and School of Medicine, State University of New York, Stony
Brook, N.Y., with kind permission of M. Barbacid, Department of Molecular
Biology, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton,
N.J. (15).
Transfection. Resting primary T cells are refractory to conventional transfec-
tion methods; therefore, it was necessary to use a prestimulation method (42).
Purified human T lymphocytes were cultured in RPMI 1640 medium containing
10% FCS, 2 mM L-glutamine, and antibiotics, supplemented with PHA at 1
mg/ml and recombinant human IL-2 (Cetus, Emeryville, Calif.) at 100 U/ml.
After 2 days of culture, the nonadherent cells were harvested, washed once with
PBS, and resuspended in RPMI 1640 medium containing 10% FCS, 2 mM
L-glutamine, and antibiotics, supplemented with only recombinant human IL-2 at
100 U/ml. The T cells were incubated for a further 2 days, washed twice with
PBS, and used for transient-transfection assays. A total of 15 3 106 T lympho-
cytes were resuspended in 400 ml of RPMI 1640 medium containing 10% FCS,
2 mM L-glutamine, antibiotics, and 100 U of IL-2 per ml, and 15 mg of reporter
plasmid DNA plus 15 mg of expression plasmid DNA were added. After a 10-min
incubation on ice, the cells were electroporated with a gene pulser (Bio-Rad
Laboratories, Richmond, Calif.) at 400 V and 960 mF. After an additional 5-min
incubation period on ice, the cells were transferred to RPMI 1640 medium
containing 10% FCS, 2 mM L-glutamine, antibiotics, and 100 U of IL-2 per ml.
At 1 h after electroporation, the cells were either left unstimulated or stimulated
with PHA plus anti-CD28 in the presence or absence of anti-CD5. Inhibitors
were added 1 h after the electroporation and 30 min before the stimulation.
After 24 h, the cells were harvested and resuspended in 150 ml of 250 mM
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Tris-HCl (pH 7.8). Total-cell extracts were prepared by five repeated freeze-thaw
cycles.
CAT ELISA. Chloramphenicol acetyltransferase (CAT) concentrations in to-
tal-cell extracts were measured with the CAT ELISA kit (Boehringer Mann-
heim) as recommended by the manufacturer. The protein concentration in the
cell extracts was determined by the Bradford assay (5), and the results of the
CAT ELISA were normalized by calculating the CAT concentration per micro-
gram of protein in the total-cell extract.
Immunoprecipitation, Western blotting, and immunodetection. T lymphocytes
(4 3 107 cells) were left unstimulated or stimulated for 5 min with PHA and
anti-CD28 in the presence or absence of anti-CD5. The cells were harvested,
washed twice with PBS, and lysed for 20 min on ice in 400 ml of lysis buffer (20
mM HEPES [pH 7.4], 2 mM EGTA, 1 mM DTT, 1% Triton X-100, 10%
glycerol) supplemented with protease inhibitors (10 mg of leupeptin [Sigma] per
ml, 10 mg of aprotinin [Sigma] per ml, 0.4 mM phenylmethylsulfonyl fluoride
[Sigma]) and phosphatase inhibitors (50 mM b-glycerophosphate, 1 mM
Na3VO4). Insoluble debris was collected by centrifugation at 1,000 3 g for 10 min
at 4°C. The protein concentration of the cell lysates was determined by the
Bradford assay (5).
To detect proteins associated with the CD5 receptor, 600 mg of cell lysate was
incubated with 4.5 mg of anti-CD5 MAb (83-P2E6) for 1 h at 4°C with rotation
and for an additional 18 h after the addition of 30 ml of protein A-agarose beads
(50% slurry). The immunoprecipitates were divided into three equal parts, cen-
trifuged in a microcentrifuge for 30 s at 4°C, washed twice with PBS, and then
boiled in 13 SDS-PAGE sample buffer. The proteins were separated by SDS-
PAGE on a 10% gel with Rainbow colored protein molecular weight markers as
a reference, and transferred onto a PVDF membrane. The membrane was
blocked for 1 h in PBS containing 5% skin milk and 0.01% Tween 20. CD5, p85
(PI 3-kinase), and Vav were detected by incubating the membranes with anti-
CD5 MAb (50% hybridoma culture supernatant), anti-p85 PAb (1:500; a kind
gift from J. A. Maassen, Department of Medical Biochemistry, University of
Leiden, Leiden, The Netherlands), and anti-Vav PAb (1:500; sc-132, Santa Cruz
Biotechnology) for 1 h and then with secondary antibodies, goat anti-mouse
Ig-HRP (1:5,000; Amersham) or swine anti-rabbit Ig-HRP (1:5,000) for 1 h. The
membranes were then assayed with the ECL detection system (Amersham).
To detect tyrosine phosphorylation of proteins, Vav and p85 (PI 3-kinase)
were immunoprecipitated from 250 mg of cell lysate by incubating it with, re-
spectively, 800 ng of anti-Vav PAb or 3 ml of anti-p85 PAb for 1 h at 4°C with
rotation and for an additional 18 h after the addition of 20 ml of protein
A-agarose beads (50% slurry). The immunoprecipitates were centrifuged in a
microcentrifuge for 30 s at 4°C, washed twice with lysis buffer, and then boiled in
13 SDS-PAGE sample buffer. The proteins were separated by SDS-PAGE on a
12.5% gel, with Rainbow colored protein molecular weight markers as a refer-
ence, and transferred onto a PVDF membrane. The membrane was blocked for
1 h in PBS containing 5% skin milk and 0.01% Tween 20. Phosphorylated
tyrosines were detected by incubating the membranes with anti-P-Tyr (PY20)-
HRP (1:1,000; sc-508-HRP [Santa Cruz Biotechnology]) for 1 h. The membranes
were then assayed with the ECL detection system. To ensure equal loading of the
proteins, the membranes were stripped of bound antibodies by being incubated
for 30 min at 55°C in stripping buffer (100 mM 2-mercaptoethanol, 2% SDS, 62.5
mM Tris-HCl [pH 6.7]) and then being incubated with primary antibodies (anti-
Vav PAb, 1:500; anti-p85 pAb, 1:500) for 1 h and then with secondary antibodies,
swine anti-rabbit Ig-HRP (1:5,000), for 1 h. The membrane was then assayed
again with the ECL detection system.
Statistical analysis. Statistical analyses of the data were performed with the
Student’s t test for paired observations. The statistical significance of the data was
at P , 0.05.
RESULTS
PI 3-kinase is involved in the CD5-induced signaling path-
way. PI 3-kinase is involved in many signaling pathways acti-
vated by lymphocyte membrane receptors, e.g., T-cell receptor
(TCR) (20), CD19 (68), CD28 (66), and IL-2R (48). PI 3-ki-
nase couples to these receptors through the SH2 domains of
the p85 subunit, which can bind several distinct tyrosine-con-
taining motifs found in the cytoplasmic domains of the recep-
tors (67). The cytoplasmic domain of the CD5 receptor also
contains such a motif with two tyrosine residues (Y-X11-Y-XX)
(3, 44). To investigate whether PI 3-kinase plays a role in the
signaling pathway activated by CD5, we performed interleu-
kin-2 (IL-2) secretion experiments with two PI 3-kinase specific
inhibitors, wortmannin (39) and LY294002 (65). Costimulation
of T lymphocytes with anti-CD5 antibodies enhanced the IL-2
secretion twofold compared with stimulation with PHA plus
anti-CD28: 1,1381 6 1,725 versus 22,868 6 3,025 pg of IL-2 per
ml (mean 6 standard error of the mean [SEM]; n 5 4; P 5
0.003). The addition of wortmannin had no effect on the PHA-
plus anti-CD28-induced IL-2 secretion: 10,399 6 1,896 pg of
IL-2 per ml (mean 6 SEM; n 5 4) but completely abrogated
the response to costimulation with anti-CD5 antibodies:
13,573 6 1,897 pg of IL-2 per ml (mean 6 SEM; n 5 4) (Fig.
1A). The addition of LY294002 to T lymphocytes stimulated
with PHA plus anti-CD28 inhibited the IL-2 secretion by 50%
(7,796 6 2,096 versus 4,023 6 996 pg of IL-2 per ml; mean 6
SEM; n 5 4; P 5 0.027). Similar to wortmannin, the increase
in the IL-2 secretion in response to CD5 costimulation of
PHA- plus anti-CD28-stimulated T cells was completely abol-
ished by the addition of LY294002: 20,408 6 5,517 pg of IL-2
per ml in the absence of LY294002 versus 4,310 6 885 pg of
IL-2 per ml in its presence (mean 6 SEM; n 5 4) (Fig. 1B).
This indicates that inhibition of the PI 3-kinase activity com-
pletely blocks the CD5 signaling pathway. In addition, we in-
vestigated whether the expression of a deletion mutant of the
p85 subunit of PI 3-kinase, Dp85 (26), could block the response
of T cells to CD5 costimulation. T lymphocytes were cotrans-
fected with an IL-2 promoter-driven CAT reporter construct
together with an empty control expression plasmid or the Dp85
expression plasmid. Costimulation of transfected control T
cells with anti-CD5 enhanced the PHA- plus anti-CD28-in-
duced CAT expression (1.8 6 0.04)-fold (mean 6 SEM; n 5
12; P , 0.001). The expression of the dominant negative p85
mutant inhibited 36% 6 5% (mean 6 SEM; n 5 3; P 5 0.017)
of the PHA- plus anti-CD28-induced CAT expression, while
the upregulation of the IL-2 promoter activity in response to
anti-CD5 was completely abrogated by the expression of Dp85
(n 5 3) (Fig. 1C).
We also determined the phosphorylation of the p85 subunit
of PI 3-kinase, since it has been reported that p85 becomes
phosphorylated on tyrosine residues before the activation of
the PI 3-kinase (2, 37). Western blotting with anti-phosphoty-
rosine antibodies after immunoprecipitation of the p85 subunit
from unstimulated or stimulated cells showed that stimulation
of T lymphocytes with PHA plus anti-CD28 induced the phos-
phorylation of p85 after only 5 min of stimulation. The subse-
quent costimulation of T lymphocytes through the CD5 recep-
tor increased the phosphorylation status of p85 extensively
(Fig. 2), which marks the significance of the PI 3-kinase activity
for the CD5-induced signaling pathway.
The effects of PI 3-kinase are not mediated through PKB or
p70 S6 kinase. The lipid products of PI 3-kinase act on mul-
tiple downstream effectors (reviewed in reference 58), includ-
ing the serine/threonine kinase PKB (also known as Akt). PKB
is directly activated by binding of PI 3,4-bisphosphate to its
pleckstrin homology (PH) domain. Binding of PI 3,4-P2 facil-
itates the dimerization of PKB, which is supposedly the mech-
anism of activation (21, 22, 33). To examine the involvement of
PKB in the CD5-induced signaling pathway, we performed a
PKB-specific kinase assay. PKB was immunoprecipitated from
T lymphocytes that were left unstimulated or stimulated with
either PHA plus anti-CD28 or PHA and anti-CD28 plus anti-
CD5, and the specific PKB kinase activity was determined by
measuring the phosphorylation of its substrate, histone 2B
(H2B). We detected a basal kinase activity of PKB present in
unstimulated T lymphocytes, which was enhanced (1.5 6 0.1)-
fold (mean 6 SEM; n 5 3; P 5 0.014) in PHA- plus anti-CD28
stimulated T lymphocytes. Costimulation with anti-CD5 did
not further increase this PKB kinase activity (n 5 3) (Fig. 3),
indicating that PKB plays no role in the CD5-induced signaling
pathway.
A second target for downstream signaling through PI 3-ki-
nase is p70 S6K. The immunosuppressive drug rapamycin im-
pedes the activation of p70 S6K (6). To investigate the role of
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p70 S6K in the CD5-induced signaling pathway, we performed
IL-2 secretion experiments with rapamycin. Costimulation of
PHA- plus anti-CD28-stimulated T lymphocytes with anti-CD5
resulted in a 2.1-fold induction of the IL-2 secretion: 4,482 6
807 versus 9,575 6 1,526 pg of IL-2 per ml (mean 6 SEM; n 5
4; P 5 0.007). In the presence of rapamycin, T lymphocytes
stimulated with PHA plus anti-CD28 secreted 76% 6 5% less
IL-2: 1,067 6 232 pg of IL-2 per ml (mean 6 SEM; n 5 4; P 5
0.047); however, costimulation with anti-CD5 subsequently en-
hanced the IL-2 secretion 2.4-fold to 2,523 6 679 pg of IL-2
per ml (mean 6 SEM; n 5 4; P 5 0.010) (Fig. 4A). To
determine whether CD5 costimulation modulates the activa-
tion of the p70 S6K kinase activity, we performed a specific
kinase assay with the S6 peptide as a substrate. We detected a
low basal kinase activity of p70 S6K present in unstimulated T
lymphocytes. Stimulation of T lymphocytes with PHA plus
anti-CD28 enhanced the p70 S6K kinase activity almost (5.4 6
0.12)-fold (mean 6 SEM; n 5 3; P 5 0.017); however, co-
stimulation with anti-CD5 did not further augment the p70
S6K kinase activity (n 5 3) (Fig. 4B), indicating that p70 S6K
plays no role in the CD5-induced signaling pathway.
Rac1 is indispensable for the CD5-induced signaling path-
way. The activation of the small GTPase Rac1 has also been
reported to be mediated through PI 3-kinase activity (27, 38,
47). To determine the involvement of Rac1 in the CD5-in-
duced signaling pathway, we used a dominant inhibitory mu-
tant of Rac1 (Rac1 z N17), which is locked in the GDP-bound
state and is unresponsive to guanine nucleotide exchange fac-
tors (49) in transfection studies. T lymphocytes were cotrans-
fected with an IL-2 promoter-driven CAT reporter construct
together with an empty control expression plasmid or the
Rac1 z N17 expression plasmid. The CAT expression of PHA-
plus anti-CD28-stimulated T cells in the control group was
FIG. 1. Inhibition of the PI 3-kinase lipid kinase activity completely abrogates the CD5-induced upregulation of the IL-2 promoter activity in activated human T
lymphocytes. (A and B) Human T lymphocytes were left unstimulated or stimulated with PHA plus anti-CD28 (aCD28) 6 anti-CD5 (aCD5) in the presence or absence
of 100 nM wortmannin (A) or 1 mM LY294002 (B), both inhibitors of PI 3-kinase. Cell-free supernatants were harvested after 24 h and analyzed for secreted IL-2
protein. The mean values 6 SEMs for the IL-2 secretion observed in four independent experiments are shown. (C) Human T cells, prestimulated as described in
Materials and Methods, were transfected with 15 mg of pCAT3e-IL-2(2319/147) together with 15 mg of either an empty control expression plasmid (control) or the
expression plasmid for a dominant negative p85 mutant (Dp85). Transfected cells were left alone for 1 h, divided into three groups, and subsequently left unstimulated
or stimulated with PHA plus anti-CD28 (aCD28) or PHA plus anti-CD28 and anti-CD5 (aCD5) for 24 h. CAT expression was measured as described in Materials and
Methods. The results are expressed as the relative CAT expression compared to the PHA- plus anti-CD28-induced CAT expression in the transfected control T cells,
which was set at 1. The mean values 6 SEMs found for the relative CAT expression in three independent experiments are shown.
FIG. 2. CD5 costimulation enhances the tyrosine phosphorylation of the p85
subunit of PI 3-kinase. T cells were left unstimulated or stimulated with PHA
plus anti-CD28 (aCD28) in the presence or absence of anti-CD5 (aCD5) for 5
min. p85 was immunoprecipitated from total-cell lysates, and tyrosine-phosphor-
ylated p85 was detected with anti-PY20 MAb (a-P-Tyr) by ECL Western blotting
as described in Materials and Methods. To ensure equal levels of immunopre-
cipitated p85, the blot was stripped and reprobed with anti-p85 PAb (a-p85). The
data are representative of three independent experiments.
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(1.8 6 0.04)-fold (mean 6 SEM; n 5 12; P ,0.001) enhanced
after costimulation with anti-CD5 (Fig. 5A). The expression of
dominant negative Rac1 blocked 58% 6 4% (mean 6 SEM;
n 5 6; P ,0.001) of the PHA- plus anti-CD28 induced CAT
expression, while the costimulatory effect of anti-CD5 was al-
most completely abolished by the expression of Rac1 z N17
(n 5 6) (Fig. 5B). Therefore, the use of a dominant inhibitory
Rac1 mutant shows that Rac1 plays a vital role in the CD5-
induced signaling pathway. Cotransfections with a constitu-
tively active Rac1 mutant (Rac1 z V12) (49) confirmed the
importance of Rac1 in the CD5 signal transduction route. The
expression of Rac1 z V12 was sufficient to induce a CAT ex-
pression in PHA- plus anti-CD28-stimulated T lymphocytes
that is comparable to the CAT expression induced in trans-
fected control T cells stimulated with PHA plus anti-CD28
and anti-CD5. Subsequent costimulation of Rac1 z V12-
transfected, PHA- plus anti-CD28- stimulated T cells with
anti-CD5 enhanced the CAT expression only slightly (n 5 3;
P 5 0.36) (Fig. 5E). To establish whether the Rac1-related
small GTPases Rho and Cdc42 are also involved in the CD5-
induced signaling pathway, we cotransfected T lymphocytes
with the IL-2 promoter-driven CAT reporter construct to-
gether with expression plasmids for dominant negative mutants
for Rho (Rho z N19) and Cdc42 (Cdc42 z N17) (14). Both Rho z
N19 and Cdc42 z N17 blocked the PHA- plus anti-CD28 in-
duced CAT expression partially with 28% 6 5% (mean 6
SEM; n 5 3; P 5 0.006) (Fig. 5C) and 35% 6 4% (mean 6
SEM; n 5 3; P 5 0.004) (Fig. 5D), respectively. However, the
expression of the dominant negative Rho and Cdc42 mutants
did not impede the upregulation of the IL-2 promoter activity
in response to CD5 costimulation: in the presence of Rho z
N19, the PHA- plus anti-CD28-induced CAT expression was
enhanced (1.9 6 0.08)-fold (mean 6 SEM; n 5 3; P ,0.001)
(Fig. 5C), and in the presence of Cdc42 z N17, the upregulation
was (1.9 6 0.12)-fold (mean 6 SEM; n 5 3; P 5 0.009) (Fig.
5D).
To assess the position of Rac1 in the CD5-induced signaling
pathway, we first used the PI 3-kinase inhibitor wortmannin.
Similar to the IL-2 secretion experiments (Fig. 1A), wortman-
nin had no effect on the PHA- plus anti-CD28-induced CAT
expression in transfected control T lymphocytes but completely
abolished the response to CD5 costimulation (n 5 3; P 5
0.010). In contrast, the expression of Rac1 z V12 made the
transfected T cells insensitive to the inhibitory effects of wort-
mannin (Fig. 5F), indicating that the expression of constitu-
tively active Rac1 can replace the PI 3-kinase-induced signal-
ing pathway. We used the CaM kinase inhibitor KN-62 to
further pinpoint the position of Rac1 in the CD5 signaling
pathway (19, 23). We have previously demonstrated that the
CD5-induced elevation of the intracellular Ca21 levels acti-
vates CaM kinase IV (23). KN-62 had no effect on the PHA-
plus anti-CD28-induced IL-2 promoter activity but completely
abrogated the costimulatory effect of anti-CD5 (n 5 3; P 5
0.007). The addition of KN-62 to Rac1 z V12-transfected T
lymphocytes reduced the CAT expression in both PHA- plus
anti-CD28-stimulated and PHA- plus anti-CD28- plus anti-
CD5-stimulated T cells to a level comparable to that in trans-
fected control T cells stimulated with PHA plus anti-CD28
(n 5 3; P 5 0.044) (Fig. 5G). These results were confirmed by
the coexpression of a dominant negative mutant of CaM kinase
IV (23) together with the constitutively active Rac1 mutant.
Similar to the experiments with KN-62, the dominant negative
CaM kinase IV mutant completely blocked the effect of Rac1 z
FIG. 3. CD5 signaling is independent of PKB activation. T cells were left
unstimulated or stimulated with PHA plus anti-CD28 (aCD28) in the presence
or absence of anti-CD5 (aCD5) for 10 min. The cells were lysed, and immuno-
precipitated PKB was assayed for kinase activity, with H2B as a substrate. To
ensure the equal precipitation of PKB, the immunoprecipitates were loaded onto
an SDS–12.5% polyacrylamide gel, and PKB protein was detected by ECL
Western blotting as described in Materials and Methods. The kinase assay shown
is representative of three independent experiments. The specific PKB kinase
activity is determined by quantification of phosphorylated H2B with a Phosphor-
Imaging system. The lower graph shows the relative phosphorylation of H2B.
The phosphorylation of H2B detected in unstimulated cells was set at 1. The
mean values 6 SEMs found in three independent experiments are shown.
FIG. 4. CD5 signaling is independent of p70 S6K activation. (A) T cells were
stimulated with PHA with or without anti-CD28 (aCD28) and anti-CD5 (aCD5)
in the presence or absence of 20 ng of rapamycin per ml. Cell-free supernatants
were harvested after 24 h and analyzed for secreted IL-2 protein. The mean
values 6 SEM for the IL-2 secretion found in four independent experiments are
shown. (B) T cells were left unstimulated or stimulated with PHA plus anti-CD28
(aCD28) in the presence or absence of anti-CD5 (aCD5) for 10 min. The cells
were lysed, and immunoprecipitated p70 S6K was assayed for kinase activity with
S6 peptide as a substrate. To ensure the equal precipitation of p70 S6K, the
immunoprecipitates were loaded onto an SDS–12.5% polyacrylamide gel, and
p70 S6K protein was detected by ECL Western blotting as described in Materials
and Methods. The kinase assay shown is representative of two independent
experiments. The specific p70 S6K kinase activity is determined by quantification
of phosphorylated S6 with a PhosphorImaging system. The lower graph shows
the relative phosphorylation of S6. The phosphorylation of S6 detected in un-
stimulated cells was set at 1. The mean values 6 SEMs found in two independent
experiments are shown.
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V12 on the IL-2 promoter activity (n 5 3; P 5 0.036) (Fig. 5H).
These results indicate that Rac1 acts downstream of PI 3-ki-
nase and upstream of the Ca21-mediated activation of CaM
kinase type IV in the CD5-induced signaling pathway.
The Rac1 guanine nucleotide exchange factor Vav is acti-
vated by the CD5-induced signaling pathway. Although the
mechanisms by which D3 phosphoinositides signal to Rac1 are
unclear, Toker and Cantley recently suggested that a PH do-
main-containing guanine nucleotide exchange factor (GEF)
might be involved (58). Vav has been shown to be a Rac1/Rho
family-specific GEF (15, 16, 25, 56), which is expressed exclu-
sively in hematopoietic and trophoblast cells (9, 31, 72). Vav
contains an array of structural motifs, including a PH domain
(36). Recent reports have shown that phosphorylation of Vav
on tyrosine residues is required for its nucleotide exchange
activity (16, 24, 25, 56, 70). To determine whether Vav is
phosphorylated upon stimulation of the CD5 receptor, we im-
munoprecipitated Vav from unstimulated or stimulated T cells
and performed Western blotting experiments with a phospho-
tyrosine-specific antibody. We could detect tyrosine-phosphor-
ylated Vav in unstimulated T lymphocytes, and the level of
tyrosine phosphorylation was not increased upon stimulation
of T cells with PHA and anti-CD28. However, Vav was exten-
sively phosphorylated on tyrosine residues upon subsequent
costimulation of the T lymphocytes with anti-CD5 (Fig. 6),
indicating that the CD5-induced signaling pathway induces the
activation of Vav. To verify that Vav plays a significant role in
the CD5-induced signaling pathway, we used both a dominant
inhibitory (Vav-C) mutant (71) and a constitutively active
[Vav(D1–65), the Vav oncogene] mutant (15) of Vav in trans-
fection studies. Costimulation of transfected control T lympho-
cytes with anti-CD5 enhanced the CAT expression (1.8 6
0.04)-fold (mean 6 SEM; n 5 12; P ,0.001) compared to that
for PHA- plus anti-CD28-stimulated T lymphocytes (Fig. 7A).
The expression of dominant negative Vav blocked 39% 6 5%
(mean 6 SEM; n 5 3; P 5 0.016) of the PHA- plus anti-CD28-
induced CAT expression in transfected T lymphocytes. Subse-
quent costimulation with anti-CD5 did not result in an en-
hancement of the CAT expression (n 5 3) (Fig. 7B). The
expression of Vav-C thus completely blocked the CD5-induced
signaling pathway, indicating that Vav is essential for this path-
FIG. 5. Rac1 is essential to the CD5 costimulatory signal pathway leading to
an upregulation of the IL-2 promoter activity, while Rho and Cdc42 play no role
in this pathway. The CD5-induced signaling pathway in T lymphocytes expressing
constitutively active Rac1 is insensitive to wortmannin but still sensitive to KN-62
or the expression of a dominant negative CaM kinase IV mutant. T cells,
prestimulated as described in Materials and Methods, were transfected with 15
mg of pCAT3e-IL-2(2319/147) together with 15 mg of either an empty control
expression plasmid (control) (A) or the expression plasmid(s) for dominant
negative or constitutively active mutants (B to H): dominant negative Rac1
(Rac1 z N17) (B), dominant negative Rho (Rho z N19) (C), dominant negative
Cdc42 (Cdc42 z N17) (D), constitutively active Rac1 (Rac1 z V12) (E to G), and
constitutively active Rac1 (Rac1 z V12) in combination with dominant negative
CaM kinase IV (H). Transfected cells were left alone for 1 h, divided into three
groups, and subsequently left unstimulated (h) or stimulated with PHA plus
anti-CD28 (n) or PHA plus anti-CD28 and anti-CD5 (z) for 24 h in the
presence of 100 nM wortmannin (F) or 10 mM KN-62 (G). CAT expression was
measured as described in Materials and Methods. The results are expressed as
the relative CAT expression compared to the PHA- plus anti-CD28-induced
CAT expression in the transfected control T cells, which was set at 1. The mean
values 6 SEMs found for the relative CAT expression in three to six independent
experiments are shown.
FIG. 6. CD5 costimulation enhances the tyrosine phosphorylation of the
Rac1-specific GEF factor Vav. T cells were left unstimulated or stimulated with
PHA plus anti-CD28 (aCD28) in the presence or absence of anti-CD5 (aCD5)
for 5 min. Vav was immunoprecipitated from total-cell lysates, and tyrosine-
phosphorylated Vav was detected with anti-PY20 MAb (a-P-Tyr) by using ECL
Western blotting as described in Materials and Methods. To ensure equal levels
of immunoprecipitated Vav, the blot was stripped and reprobed with anti-Vav
pAb (a-p85). The data are representative of three independent experiments.
1730 GRINGHUIS ET AL. MOL. CELL. BIOL.
way. The expression of the Vav oncogene, a constitutively
active mutant, resulted in a strong increase in the CAT expres-
sion even when the transfected T cells were stimulated only
with PHA plus anti-CD28: a (3.2 6 0.19)-fold (mean 6 SEM;
n 5 3; P 5 0.007) induction was observed compared to that for
transfected control T cells stimulated with PHA plus anti-
CD28. The subsequent costimulation of Vav(D1–65)-trans-
fected, PHA- plus anti-CD28-stimulated T lymphocytes with
anti-CD5 did not result in a further enhancement of the CAT
expression (n 5 3) (Fig. 7C), which implies that the CD5-
induced signaling pathway has been activated.
To establish the position of Vav in the CD5-induced signal-
ing pathway, we performed cotransfection experiments with
the IL-2 promoter-driven CAT reporter construct together
with the constitutively active Vav oncogene, Vav(D1–65), in
the presence of the PI 3-kinase inhibitor wortmannin. Wort-
mannin had no effect on the Vav(D1–65)-induced CAT expres-
sion (n 5 3) (Fig. 7D), indicating that PI 3-kinase is a upstream
effector of Vav. Both the CaM kinase inhibitor KN-62 and the
expression of a dominant negative CaM kinase IV mutant
partially blocked the Vav(D1–65)-induced CAT expression in
transfected T cells stimulated with either PHA plus anti-CD28
or PHA plus anti-CD28 and anti-CD5: 31% 6 2% (mean 6
SEM; n 5 3; P 5 0.006) (Fig. 7E) and 34% 6 2% (mean 6
SEM; n 5 3; P ,0.001) (Fig. 7F), for KN-62 and dominant
negative CaM kinase IV, respectively. This result suggests that
CaM kinase IV acts as a downstream effector in some signaling
pathways mediated by Vav, including the CD5-induced signal-
ing pathway.
Cotransfection experiments with constitutively active Vav
and dominant negative Rac1 indicate that Rac1 acts down-
stream of Vav, since the CAT expression induced by either
PHA plus anti-CD28 or PHA plus anti-CD28 and anti-CD5
stimulation was similar to that induced in Rac1 z N17-trans-
fected T lymphocytes (n 5 3) (Fig. 7G). In addition, the ex-
pression of dominant negative Vav did not inhibit the CAT
expression induced by the expression of the constitutively ac-
tive Rac1 mutant Rac1 z V12 in PHA- plus anti-CD28- or
PHA- plus anti-CD28- plus anti-CD5-stimulated T lympho-
cytes (n 5 3) (Fig. 7H).
The p85 subunit of PI 3-kinase and Vav are associated with
the CD5 receptor. It has been previously reported that Vav can
associate with the p85 subunit of PI 3-kinase (46, 52, 68). To
determine whether this association is present at the cytoplas-
mic domain of the CD5 receptor, we performed Western blot-
ting experiments after immunoprecipitating the CD5 receptor
from either unstimulated or stimulated T lymphocytes. The
CD5 receptor became associated with both p85 and Vav after
a 5-min stimulation of the T cells with PHA plus anti-CD28,
and this association remained unchanged after costimulation
with anti-CD5 (Fig. 8).
DISCUSSION
CD5 acts as a coreceptor on T lymphocytes and plays an
important role in T-cell signaling and T-cell–B-cell interactions
through interactions with its counterreceptor CD72 on B lym-
phocytes (1, 4, 13). Upon engagement of the TCR by ligand,
the cytoplasmic domain of CD5 is phosphorylated on several
tyrosine residues by p56lck. It has also been demonstrated that
p56lck can subsequently bind to the CD5 receptor through its
SH2 domain and becomes fully activated through autophos-
phorylation (18, 44). It remains unknown what further signal-
ing events take place once the CD5 receptor is stimulated,
although it has been demonstrated that costimulation of T
lymphocytes with anti-CD5 antibodies augments the intracel-
FIG. 7. Vav plays a major role in the CD5 signal pathway leading to an
upregulation of the IL-2 promoter activity, as an upstream effector of Rac1. The
signaling pathways in T lymphocytes expressing constitutively active Vav are
insensitive to wortmannin but still sensitive to KN-62 or the expression of a
dominant negative CaM kinase IV mutant. T cells, prestimulated as described in
Materials and Methods, were transfected with 15 mg of pCAT3e-IL-2(2319/
147) together with 15 mg of either an empty control expression plasmid (control)
(A) or the expression plasmid(s) for dominant negative or constitutively active
mutants (B to H): dominant negative Vav (Vav-C) (B), constitutively active Vav
[Vav(D1–65)] (C to E), constitutively active Vav [Vav(D1–65)] in combination
with dominant negative CaM kinase IV (F), constitutively active Vav [Vav(D1–
65)] in combination with dominant negative Rac1 (Rac1 z N17) (G), and con-
stitutively active Vav [Vav(D1–65)] in combination with constitutively active
Rac1 (Rac1 z V12) (H). Transfected cells were left alone for 1 h, divided into
three groups, and subsequently left unstimulated (h) or stimulated with PHA
plus anti-CD28 (n) or PHA plus anti-CD28 and anti-CD5 (z) for 24 h in the
presence of 100 nM wortmannin (D) or 10 mM KN-62 (E). CAT expression was
measured as described in Materials and Methods. The results are expressed as
the relative CAT expression compared to the PHA- plus anti-CD28-induced
CAT expression in the transfected control T cells, which was set at 1. The mean
values 6 SEMs found for the relative CAT expression in three independent
experiments are shown.
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lular Ca21 and cyclic GMP levels and activates the CaM kinase
IV, which leads to the activation of the transcription factor
AP-1 (23, 30, 35). In this study, we have examined the initial
signaling events, induced by ligation of the CD5 receptor,
which are required for the elevation of the intracellular Ca21
levels. We show that activation of PI 3-kinase is a proximal and
essential step in the CD5 signaling pathway. The p85 subunit of
PI 3-kinase is heavily phosphorylated on tyrosine residues
within 5 min upon costimulation of T lymphocytes through the
CD5 receptor. The phosphorylation of p85 is required to in-
duce the lipid kinase activity of the p110 subunit (2, 37), al-
though the protein tyrosine kinase responsible for this phos-
phorylation event has yet to be identified. Inhibition of the
lipid kinase activity of PI 3-kinase with either wortmannin or
LY294002 completely blocks the CD5 costimulatory signal, as
assessed in IL-2 secretion experiments. Expression of a dele-
tion mutant of p85, which lacks a binding site for the p110
subunit, also blocks the upregulation of the IL-2 promoter
activity in response to CD5 costimulation. Recently, Dennehy
et al. showed that the SH2 domains of the p85 subunit of PI
3-kinase can bind to the tyrosine-phosphorylated motifs in the
cytoplasmic domain of the CD5 receptor in pervanadate-stim-
ulated thymocytes (18), which supports our findings that acti-
vation of PI 3-kinase represents an early signaling event of the
CD5 signaling pathway.
We demonstrate that the effects of PI 3-kinase activity in the
CD5-induced signaling pathway are not mediated through the
known downstream effectors PKB (21, 33) and p70 S6K (43).
The kinase activity of PKB is not increased by costimulation of
T cells through the CD5 receptor. The activity of PKB is
directly mediated by the binding of the PI 3-kinase lipid prod-
uct PI 3,4-P2 to its PH domain (21, 22, 33), which implies that
the activation of PI 3-kinase in response to CD5 ligation results
in the generation of other D3 phosphoinositide products than
PI 3,4-P2. The kinase activity of p70 S6K is also not affected by
costimulation of T lymphocytes with anti-CD5. In addition,
rapamycin, an inhibitor of p70 S6K activation, is unable to
block the CD5-induced increase of the IL-2 secretion by PHA-
plus anti-CD28-stimulated T lymphocytes.
We show that the effects of PI 3-kinase are completely me-
diated through the small GTPase Rac1 and not by the Rac1-
related GTPases Rho and Cdc42. The expression of a domi-
nant inhibitory Rac1 mutant completely abolishes the response
of transfected T cells to CD5 costimulation, while the expres-
sion of a constitutively active Rac1 mutant makes costimula-
tion through CD5 superfluous. These results show that Rac1 is
indispensable for the CD5-induced signaling pathway. The PI
3-kinase inhibitor wortmannin is unable to repress the CD5
signal in transfected T lymphocytes expressing constitutively
active Rac1, indicating that Rac1 acts downstream from PI
3-kinase; this is supported by studies from other groups (27, 38,
47). Nobes et al. suggested that the production of PI 3,4,5-P3
by PI 3-kinase is required for the activation of Rac1 by platelet-
derived growth factor in NIH 3T3 cells, resulting in actin po-
lymerization at the plasma membrane (38). The regulation of
signaling proteins through the D3 phosphoinositide products
of PI 3-kinase are often mediated through PH domains. Indi-
vidual PH domains have evolved specificity for PI 3,4-P2, PI
4,5-P2 or PI 3,4,5-P3 (32, 45, 58). Rac1 contains no such PH
domain. Toker and Cantley had already suggested that a PH
domain containing GEF might be involved in the activation of
Rac1 in response to increased cellular concentrations of D3
phosphoinositides (58). Vav is a Rac1-specific GEF and also
contains a PH domain among several structural motifs (16, 36,
56), suggesting that Vav is a potential candidate for the regu-
lation of Rac1 through the lipid products of PI 3-kinase. In-
deed, transfection experiments with dominant inhibitory and
constitutively active Vav mutants confirm that Vav plays an
essential role in the CD5-induced signaling pathway. Similar to
the transfection experiments with the Rac1 mutants, we ob-
serve that dominant negative Vav completely abrogates the
CD5 costimulatory response while constitutively active Vav
fully activates the CD5 signaling pathway, making CD5 co-
stimulation dispensable. Transfection experiments confirm
that Vav is a downstream effector of PI 3-kinase and an up-
stream effector of Rac1. It is also shown that Vav becomes
extensively phosphorylated on tyrosine residues upon CD5 co-
stimulation, which is a prerequisite for activation of the ex-
change activity (16, 25, 56). Vav can be phosphorylated by
several protein tyrosine kinases, like p56lck (16, 25), Syk (56),
and Tyk2 (62). Since p56lck associates with the CD5 receptor
and subsequently becomes fully activated through autophos-
phorylation (44), it seems to be a major candidate for the
CD5-induced tyrosine phosphorylation of Vav. Some reports
suggest that Vav associates with the p85 subunit of PI 3-kinase
(42, 52, 68). The association between Vav and p85 might serve
to recruit Vav to the multiprotein complex at the CD5 recep-
tor, which brings it into close proximity with p56lck, resulting in
phosphorylation of Vav in response to CD5 costimulation.
This is supported by the finding that both PI 3-kinase (p85) and
Vav can be detected in anti-CD5 immunoprecipitates from
stimulated T lymphocytes. The observation that both p85 and
Vav associate with the CD5 receptor after T-cell receptor
activation but are tyrosine phosphorylated only after CD5 re-
ceptor activation implies that CD5 stimulation is essential to
induce the activity of a protein tyrosine kinase or to bring p85
and Vav in close proximity to an already activated protein
tyrosine kinase, like p56lck. Further experiments are necessary
to fully understand the regulation of Vav through binding of
D3 phosphoinositide products of PI 3-kinase to its PH domain
and to identify the protein tyrosine kinases that are responsible
for its phosphorylation upon ligation of the CD5 receptor.
The activation of both Vav and Rac1 precedes the activation
of CaM kinase IV by the CD5 signaling pathway. The CaM
kinase inhibitor KN-62 and the expression of a dominant neg-
ative CaM kinase IV mutant are able to block the CD5 signal-
FIG. 8. The CD5 receptor is associated with p85 (PI 3-kinase) and Vav. T
cells were left unstimulated or stimulated with PHA plus anti-CD28 (aCD28) in
the presence or absence of anti-CD5 (aCD5) for 5 min. CD5 was immunopre-
cipitated from total-cell lysates, and CD5, p85, and Vav were detected by ECL
Western blotting as described in Materials and Methods.
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ing pathway even in T cells that are transfected with the con-
stitutively active Vav and Rac1 mutants. CaM kinase IV is
directly activated by the CD5-induced elevations of the intra-
cellular Ca21 concentration (23), which implies that Rac1 is
involved in the regulation of these elevations. The downstream
effectors of Rac1 in the CD5-induced signaling pathway, pos-
sibly involved in the opening of membrane localized Ca21
channels, remain elusive. It has previously been demonstrated
that the downstream effectors of Rac1, JNK and p38/Mpk2,
are not involved in the CD5-induced signaling pathway (23).
These observations suggest that a signaling pathway, distinct
from the mitogen-activated protein kinase cascades and prob-
ably more closely related to the pathways involved in the Rac1-
induced reorganization of the actin cytoskeleton (29, 34, 38, 49,
55, 69), is activated by Rac1 in response to CD5 costimulation
of T lymphocytes. Further experiments are necessary to iden-
tify the downstream targets for Rac1 in the CD5 signaling
pathway and to clarify how these effectors induce the observed
Ca21 influx.
Based on our results and the observations by other groups,
we propose a model for the signaling pathway induced by CD5
costimulation, which is mediated through PI 3-kinase, Vav, and
Rac1 (Fig. 9). Upon TCR engagement by ligand, the tyrosine
residues in the cytoplasmic domain of the CD5 receptor are
phosphorylated by p56lck. p56lck associates with the CD5 re-
ceptor through its SH2 domain and becomes fully activated
through autophosphorylation. The phosphorylated tyrosine
residues serve as docking sites for the SH2 domains of the p85
subunit of PI 3-kinase. Vav associates with the p85 subunit of
PI 3-kinase, which serves to recruit Vav to the complex at the
CD5 receptor. It is conceivable that upon stimulation of the
CD5 receptor, a conformational change of the cytoplasmic
domain occurs, which brings both p85 and Vav in close prox-
imity to a protein tyrosine kinase, most probably the CD5-
associated p56lck. PI 3-kinase is subsequently phosphorylated
on tyrosine residues, which indirectly activates the lipid kinase
activity of the p110 subunit. Vav is also phosphorylated on
tyrosine residues, which is necessary to activate its nucleotide
exchange activity. The PI 3-kinase lipid product PI 3,4,5-P3, or
another product, binds to the PH domain of Vav, which results
in the full activation of Vav. Finally, Vav activates Rac1 by
exchanging GDP for GTP, leaving Rac1 in the activated GTP-
bound state.
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